Home Weight loss (GLP-1) By state Pennsylvania
Pennsylvania Medicaid's GLP-1 Cutoff: 8 programs ship to PA
Pennsylvania paid for GLP-1 weight-loss drugs through Medical Assistance from January 2023, which few states did. That ended on January 1, 2026 for adults 21 and older, a year after Independence Blue Cross dropped the same coverage for its fully insured group and individual members in southeastern Pennsylvania. Here is what each change means, and how people here are staying on treatment for far less than retail. The lowest price we found from a program that ships to Pennsylvania: compounded semaglutide at $89 a month on a 12-month plan ($99 month to month) at Lttl.
Pennsylvania at a glance
- Pennsylvania Medicaid
- Does not cover for weight loss
- State employee plan
- Not published
- Adults with obesity
- 33.5% (2025)
- Programs we compare that ship to PA
- 8 of 22
Online GLP-1 programs for Pennsylvania, cheapest first
Programs that ship to Pennsylvania. Prescribed online by a licensed clinician; medication and delivery included.
How we pick and check programs
Our pick for November 2026

A daily oral GLP-1 plan. No needles, no injections
Compounded semaglutide in Pennsylvania: lowest monthly price
| # | Program | Lowest price | Month to month | Link |
|---|---|---|---|---|
| 1 | LttlCheapest | $89/mo 12-month plan | $99 / 4 wks | VisitLttl |
| 2 | BetterMe Rx | $99/mo 12-month plan | $199/mo | VisitBetterMe Rx |
| 3 | Refills | $99/mo | $99 / 4 wks | VisitRefills |
| 4 | Direct Meds | $297/mo | $297/mo | VisitDirect Meds |
| 5 | Gala | From $69/mo starting price, plan length not stated | Not stated | VisitGala |
| 6 | TrimRx | From $349/mo starting price, plan length not stated | Not stated | VisitTrimRx |
Compounded tirzepatide in Pennsylvania: lowest monthly price
| # | Program | Lowest price | Month to month | Link |
|---|---|---|---|---|
| 1 | MaximusCheapest | $99.99/mo 12-month plan | Not offered | VisitMaximus |
| 2 | Lttl | $139/mo 12-month plan | $149 / 4 wks | VisitLttl |
| 3 | BetterMe Rx | $159/mo 12-month plan | $249/mo | VisitBetterMe Rx |
| 4 | Refills | $159/mo | $159 / 4 wks | VisitRefills |
| 5 | Direct Meds | $399/mo | $399/mo | VisitDirect Meds |
| 6 | Gala | From $99/mo starting price, plan length not stated | Not stated | VisitGala |
| 7 | TrimRx | From $279/mo starting price, plan length not stated | Not stated | VisitTrimRx |
- Low month-to-month#1
Up to $140 off your first monthCompounded semaglutide for $99, month to month
Semaglutide$99/momonth to month (4-week supply); $89 on a 12-month planVisit Lttl Read our Lttl review - Pills or shots#2
Semaglutide from $99/moChoose weekly shots or daily tablets; shots from $99/mo on the 12-month plan
Semaglutide shots from$99/moon the 12-month plan; $199 month to monthVisit BetterMe Rx Read our BetterMe Rx review - No contract#3
Fall sale: 40% offCompounded semaglutide as low as $99 a month
Semaglutide as low as$99/moper 4-week supply, month to month; shown during a 40% fall sale4.2 on Trustpilot1,779 reviews ·Visit Refills Read our Refills review - Low-cost tirzepatide#4
Same price at every doseCompounded tirzepatide from $99.99 a month
Tirzepatide from$99.99/moon the 12-month plan, paid up front; $199.99 on 2 months4.4 on Trustpilot1,106 reviews ·Visit Maximus Read our Maximus review - Delivery in 1-2 days#5
Fall sale: $150 offSame price at every dose, at your door in 1-2 days
Semaglutide$297/momonth to month: medication, doctor visits and shipping included; tirzepatide $399; fall sale: "starting at $147", "$150 off"4.5 on Trustpilot17,724 reviews ·Visit Direct Meds Read our Direct Meds review
3 more programs are in the price tables above.
After Medical Assistance: how Pennsylvanians are staying on treatment
The state announced the change in a Medical Assistance Bulletin dated November 24, 2025. Everyone whose GLP-1 was paid for by Medicaid got a letter saying coverage for weight loss would end on December 31, 2025. Adults can still get GLP-1s covered for type 2 diabetes, and possibly for conditions like sleep apnea, if they meet prior authorization rules. Children and young adults under 21 keep a path through the federal EPSDT benefit.
Researchers at the University of Pennsylvania's Leonard Davis Institute warned the cut would abruptly disrupt care for patients who were doing well on these drugs. Pennsylvania still covers one or more older, non-GLP-1 weight-loss drugs, according to KFF. For many patients, though, those aren't the medicine they started on.
One fix is an online cash program. Compounded semaglutide and tirzepatide programs that ship to Pennsylvania list their own monthly prices, and several keep that price the same as the dose goes up. If you want to stay on a brand-name drug, programs like Maximus offer Wegovy and Zepbound too. The table on this page lines them up.
- Pennsylvania Medical Assistance stopped covering GLP-1s for weight loss for adults 21 and older on January 1, 2026, per Medical Assistance Bulletin issued November 24, 2025. (pa.gov)
- The Pennsylvania Health Law Project notes that members under 21 may still receive GLP-1s for weight loss under EPSDT, and adults may qualify for other conditions such as type 2 diabetes. (phlp.org)
- Penn's Leonard Davis Institute wrote that the change would abruptly disrupt care for patients benefiting from GLP-1s. (ldi.upenn.edu)
- KFF notes Pennsylvania Medicaid still covers one or more non-GLP-1 weight-loss drugs. (kff.org)
- Pennsylvania's adult obesity rate was 33.5% in 2025. (cdc.gov)
- The bulletin adds a GLP-1 Receptor Agonists class to Pennsylvania's Statewide PDL, requires prior authorization for every GLP-1 prescription, and voids prior approvals issued before January 1, 2026. (pa.gov)
- Under the same bulletin, Saxenda is no longer covered for any indication, while preferred non-GLP-1 obesity drugs such as phentermine remain available without prior authorization within quantity limits. (pa.gov)
- Independence Blue Cross stopped covering drugs prescribed solely for weight loss for fully insured group and individual Commercial members on January 1, 2025, while continuing GLP-1 coverage with prior authorization for type 2 diabetes and cardiovascular disease. (provcomm.ibx.com)
- IBX's Select Drug Program and Value formularies ended coverage of Zepbound for obstructive sleep apnea for new prescriptions on May 1, 2025; members with an employer weight-loss benefit keep GLP-1 coverage. (provcomm.ibx.com)
- In 2025, 40.8% of Pennsylvania adults aged 40 to 59 had obesity, compared with 27.8% of adults 18 to 39. (cdc.gov)
What the Medical Assistance bulletin made everyone redo
The November 24, 2025 bulletin did more than end weight-loss coverage. It created a new GLP-1 Receptor Agonists class on the Statewide Preferred Drug List, and every prescription in that class now needs prior authorization, whatever it is for. Approvals issued before the change stopped being valid after December 31, 2025, so prescribers had to file fresh requests in January even for patients using Ozempic or Mounjaro for diabetes. The rules apply in fee-for-service and in the managed care plans alike.
Two other details matter. Saxenda is no longer covered for any reason. And the older obesity drugs that are not GLP-1s stay covered: preferred ones such as phentermine can be filled without prior authorization as long as the quantity limits are respected.
Independence Blue Cross went first, in 2025
In the Philadelphia region, the commercial cut came a year earlier. On January 1, 2025, Independence Blue Cross stopped covering GLP-1 and other drugs prescribed solely for weight loss as a standard benefit for its fully insured group and individual members. People who kept taking them had to pay the full price from that date or from their plan's renewal. IBX said the drugs cost almost 10 times more in the U.S. than elsewhere and that higher premiums hit every member. Coverage stayed, with prior authorization, for type 2 diabetes and heart disease.
The cut didn't stop at weight loss. On May 1, 2025, IBX's Select Drug Program and Value formularies also stopped covering Zepbound for obstructive sleep apnea for new prescriptions. Members whose employer buys a weight-loss drug benefit kept GLP-1 coverage, Zepbound included. If you work in Bucks, Chester, Delaware, Montgomery or Philadelphia county, the first question for HR is whether your group opted in.
Pennsylvania's obesity numbers peak in middle age
The CDC's 2025 survey put Pennsylvania's adult obesity rate at 33.5%. The age split tells more: 27.8% of adults 18 to 39, 40.8% of adults 40 to 59, and 32.9% of those 60 and older.
Older Pennsylvanians have one new route. Since July 1, 2026, the federal Medicare GLP-1 Bridge gives eligible Part D enrollees certain GLP-1 weight-loss drugs for a $50 copay, through the end of 2027. For working-age adults outside it, a cash program that ships to Pennsylvania is the usual answer, and the table on this page compares them by full monthly price.
GLP-1 in Pennsylvania: questions
When did Pennsylvania Medicaid stop covering GLP-1s for weight loss?
On January 1, 2026, for adults 21 and older. The change was announced in a Medical Assistance Bulletin issued November 24, 2025, and members got letters saying coverage would end December 31, 2025. Pennsylvania had covered these drugs for weight loss since January 2023. If you lost coverage, the self-pay programs compared on this page are the most common next step.
My child is on Pennsylvania Medicaid. Can they still get Wegovy?
Possibly. The Pennsylvania Health Law Project explains that under EPSDT, a Medicaid plan can't simply refuse GLP-1s for weight loss for members under 21. Requests are reviewed for medical necessity. Talk with your child's doctor about submitting one. For adults in the household who lost coverage, the cash programs on this page are an option.
Will PA Medicaid still cover my GLP-1 if I have type 2 diabetes?
Yes, if you meet the prior authorization rules. Pennsylvania Medical Assistance continues to cover GLP-1s such as Ozempic and Mounjaro for adults with a documented type 2 diabetes diagnosis. The January 2026 change only removed coverage when weight loss is the reason. If weight is your main goal, compare the self-pay options listed above.
What does semaglutide cost in Pennsylvania without insurance?
Compounded semaglutide from online programs is the lowest-priced route among the programs we compare. At our November 2026 check, several programs that ship to Pennsylvania listed prices under $200 a month, and lower on three- or twelve-month plans. Prices are the same whether you live in Philadelphia, Pittsburgh or Erie. See the current list in the table above.
Can I appeal the Pennsylvania Medicaid GLP-1 denial for weight loss?
You can always appeal a denial, and the Pennsylvania Health Law Project publishes free guides on how. For adults, though, the weight-loss benefit itself was removed, so appeals work best when there's a separate medical reason, such as diabetes or sleep apnea. While you sort that out, a self-pay program can keep you on treatment.
Does Independence Blue Cross cover Wegovy for weight loss?
Not as a standard benefit. Since January 1, 2025, IBX has excluded drugs prescribed only for weight loss for its fully insured group and individual members. Employers can opt in to a weight-loss benefit, and some do. Wegovy and other GLP-1s stay covered with prior authorization for type 2 diabetes and heart disease. If your group didn't opt in, compare the cash programs above.
Does Pennsylvania Medicaid cover Zepbound for sleep apnea?
It can, with prior authorization. Pennsylvania's 2026 rules end GLP-1 coverage only for overweight and obesity. Other medically accepted uses, including obstructive sleep apnea, can still be approved. Your prescriber files the request through the Medical Assistance prior authorization process or your managed care plan. Weight loss alone is not an accepted reason.
Can I get a GLP-1 prescribed online in Pennsylvania?
Yes. The programs above say on their own sites that they serve Pennsylvania.